A new sildenafil analogue, cyclopentynafil (1) and a new tadalafil analogue, N-octylnortadalafil (2) were isolated from a dietary supplement illegally marketed for erectile dysfunction. The structures of the sildenafil and tadalafil analogues were elucidated by using HPLC-photodiode array (PDA), LC-MS, high-resolution MS, NMR and circular dichroism (CD). These compounds were determined to be 5- In this paper, we report the analysis and structural elucidation of a new sildenafil analogue, cyclopentynafil and a new tadalafil analogue, N-octylnortadalafil, that were isolated from a dietary supplement illegally marketed for erectile dysfunction.
Recently, along with the rise in health consciousness, the consumption of dietary supplements has increased year by year. In Japan, some of these products are illegally advertised as effective for sexual enhancement. Consumers take these products without knowing that most are adulterated with synthetic compounds, such as sildenafil ( Fig. 1 ), vardenafil and tadalafil ( Fig. 1 ), all of which are known as active drug ingredients for the treatment of penile erectile dysfunction (ED). [1] [2] [3] In our previous paper, we identified a new tadalafil analogue, chloropretadalafil, 4) which had been synthesized as a tadalafil precursor, 5) from a dietary supplement along with hydroxyhomosildenafil and aminotadalafil.
Thus far, a large number of analogues of sildenafil, tadarafil and vardenafil have been reported, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] while a new type of phosphodiesterase-5 (PDE-5) inhibitor, (R)-xanthoanthrafil, an anthranilic acid derivative, has been found in a dietary supplement advertising sexual enhancement for men. 24) (R)-Xanthoanthrafil was first synthesized as a candidate compound for the treatment of ED by Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc., Tokyo, Japan), 25) and was reported as a PDE-5 inhibitor, FR226807, after the manufacturer discontinued the process of developing the drug for approval. Furthermore, another new type of PDE-5 inhibitor, thioquinapiperifil, an imidazoquinazoline derivative, was also detected in a dietary supplement. 26) This compound was first synthesized as KF31327 by Kyowa Hakko Kogyo Co., Ltd., and Hirose et al. reported that it was a more potent and selective PDE-5 inhibitor than sildenafil. [27] [28] [29] In this paper, we report the analysis and structural elucidation of a new sildenafil analogue, cyclopentynafil and a new tadalafil analogue, N-octylnortadalafil, that were isolated from a dietary supplement illegally marketed for erectile dysfunction.
Results and Discussion
In this study, we reported 1 and 2 as newly isolated compounds from an illegal dietary supplement. Figure 2A shows the HPLC chromatograms of an extract of the supplement. Two main peaks were detected in the extract, one at 20.9 min (compound 1) and the other at 37.2 min (compound 2). The PDA-sliced UV spectrum of 1 exhibited a quite similar profile (l max nm: 218, 290, Fig. 2B ) to that of sildenafil; however, 1 eluted at a later retention time (20.9 min) than sildenafil (18.3 min) under the same chromatographic conditions. Meanwhile, the PDA-sliced UV spectrum of 2 showed a quite similar profile (l max nm: 281, Fig. 2C H COSY and HMQC spectra of 1 indicated the presence of a cyclopentyl group (Fig. 4) . The connectivity of this group was deduced from the HMBC spectrum (Fig. 4) . The methine proton at d 2.51 (H-29) of the cyclopentyl group showed correlations to the methylene carbons at d 51.2 (C-25, C-27) of sildenafil. These data determined the structure of 1 as 5-[2-ethoxy-5-(4-cyclopentylpiperazin-1-ylsulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo [4,3- H COSY and HMQC spectra of 2 indicated the presence of an N-octyl group (Fig. 5) . The connectivity of an N-octyl group was deduced from the HMBC spectrum (Fig. 5) . The methylene proton at d 3.49 (H-13) of the N-octyl group showed correlations to the carbonyl carbon at d 169.1 (C-1) and a methylene carbon at d 51.2 (C-3) of tadalafil. Also, methylene protons at d 3.94 and 4.24 (H 2 -3) showed correlations to the methylene carbon at d 47.2 (C-13). These data determined the planar structure of 2, as shown in Fig. 5 .
The relative configuration between two methine protons at C-6 and C-12a was established a cis configuration by the NOE experiment. Furthermore, the CD spectrum of 2 is superimposable with that of tadalafil (Fig. 6) , and it is clear that the absolute stereochemistry of two methine protons at C-6 and C-12a are the same as that of tadalafil. These results enabled us to elucidate the structure of 2 as (6R,12aR)-6- Table 2 . Considering its properties, compound 2 is designated as N-octylnortadalafil.
Furthermore, quantitative analyses of 1 and 2 in the supplement product were determined by HPLC. The contents of 1 and 2 in the product were about 130 mg/tablet (301 mg/mg) and about 27 mg/tablet (64.1 mg/mg), respectively.
Finally, we calculated to make docking models of 1 and 2 bound to PDE-5. Compounds 1 and 2 were well fitted to the cavity of PDE-5 like sildenafil and tadarafil, respectively. Therefore, both compounds are expected to have inhibitory activities against PDE-5.
In conclusion, a new sildenafil analogue, cyclopentynafil and a new tadalafil analogue, N-octylnortadalafil were isolated from a dietary supplement illegally marketed in Japan for erectile dysfunction. Their structures were elucidated by using HPLC-PDA, LC-MS, high-resolution MS, NMR and CD. Recently, Toque et al. synthesized a new cyclohexyl type of sildenafil analogue and its IC 50 value as PDE-5 inhibitor was almost same as sildenafil, 30) whereas cyclopentynafil and N-octylnortadalafil are the first compounds reported to be new sildenafil and tadalafil analogues, respectively, and their inhibitory activities against PDE-5 are expected by docking study. Thus, tremendous risk is faced by patients who unknowingly look to dietary supplements, which are adulterated with such analogues for ED treatment.
